AATCC Review Article Describes Stay-Fresh® Antimicrobial Technology

September 10, 2013

GAINESVILLE, FL--(Marketwired - September 10, 2013) - Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that its Stay Fresh technology is featured in AATCC Review (http://www.aatcc.org/media/), the journal of the American Association of Textile Colorist and Chemists. The AATCC is a not for profit association of textile professionals, and a leader in development of standards and for knowledge about textiles and textile processing.

"We are very pleased that AATCC elected to publish this scientific article detailing our peroxide based antimicrobial technology. Our Stay Fresh technology can add functionality and value to textiles, as well as preserve hygiene and freshness. It also protects textiles from microbial degradation during all parts of their life cycle -- from production and inventory preservation through to providing added comfort for the end user," said Bernd Liesenfeld, Quick-Med's President and lead author for the publication. The article details testing showing strong antimicrobial efficacy even after multiple launderings, and presents substantiating analytical testing data that document how the peroxide functionalization provides superior durability compared to many other antimicrobial finishes.

About Stay Fresh
Stay Fresh is Quick-Med's newest technology platform. This technology is based on hydrogen peroxide -- a well known consumer antimicrobial product that is commonly used in households for disinfecting cuts, scrapes, toothbrushes, etc. Due to its green credentials, Hydrogen Peroxide is also seeing increasing use in household cleaning products targeting environmentally conscious consumers. Hydrogen peroxide is also produced by human cells to combat invasive bacteria, and is a naturally occurring preservative component of milk and honey. EPA has registered Stay Fresh to be utilized to protect a broad selection of treated goods for consumer use, including textiles, decorative fabrics, and functional fabrics such as filters and carpets. FDA has also granted clearance to market an antibacterial medical textile based on Stay Fresh Technology. The Stay Fresh technology offerings provided by Quick-Med are expanding continuously, with development of additional applications including antimicrobial surface treatments, and superabsorbent antimicrobial powders to complement the range of products that are already cleared for consumer use under EPA or FDA jurisdiction.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing. Its Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications, with consumer applications of Stay Fresh Technology having EPA registration for the treated articles, as well as an FDA clearance for an antibacterial medical textile product. Quick-Med develops antimicrobial technologies to promote public health, safety and comfort. For more information, see: www.quickmedtech.com.

© 2013 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®, and Stay Fresh® are registered trademarks of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

Contact Information

CONTACT:
Quick-Med Technologies
Bernd Liesenfeld, President
(352) 379-0611
bliesenfeld@quickmedtech.com